Germany’s specialty glass company SCHOTT AG and Serum Institute of India, the world‘s largest vaccine producer and manufacturer of biologics, have formed a joint venture for pharma packaging products such as vials, syringes, ampoules and cartridges.
Serum Institute bought the 50% stake in the Indian joint venture SCHOTT Kaisha from former co–owners Kairus Dadachanji and Shapoor Mistry
Serum Institute of India CEO, Adar Poonawalla, said, “Even the best medication can’t reach the patient without the right packaging. Securing this supply chain is of strategic importance. SCHOTT is the perfect partner for us to do this because of their expertise and global network.”
Dr. Frank Heinricht, CEO SCHOTT, said, “As India has steadily established its position as a global pharmaceutical hub, we are delighted to strengthen our footprint within the Indian pharma supply chain. It is an excellent example of shifting towards new cooperation models, with greater synergies between pharma manufacturing and packaging production.”
The joint venture will definitely continue to supply its customers in India and abroad as a reliable partner, says Eric L’Heureux, the new managing director and former longstanding Head of Operations. “We have significantly increased our production capacity in India. Over the last three years we have invested roughly Rs. 600 crores to set up two new plants in Umarsadi, Gujarat and Baddi, Himachal Pradesh, to secure uninterrupted supply in our existing facilities during the pandemic.”
Last updated: December 26th, 2025
